Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MIRM vs ELDN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MIRM Captures Overall Composite Edge (51.1 HOLD vs 44.3 HOLD), While ELDN Leads 3–2 on Growth & Valuation Pillars

MIRM Overall Winner 6-Pillar Tally: MIRM 2 – 3 ELDN (1 Tie) Matrix Metrics: MIRM 5 – 5 ELDN

As of Nov 20, 2026, Mirum Pharmaceuticals, Inc. (MIRM) captures the overall head-to-head institutional edge over Eledon Pharmaceuticals, Inc. (ELDN) on higher Unified Composite conviction (51.1/100 HOLD vs. 44.3/100 HOLD) after splitting the core matrix 5–5 (led by Growth & Scale, Options & Positioning), while ELDN wins 3–2 across the 6-pillar growth and valuation breakdown. MIRM trades at $96.13 (N/M Forward P/E, -21.6% operating margin) versus ELDN at $1.78 (5.4x Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: MIRM earns the overall head-to-head edge with a stronger Unified Composite Score (51.1/100 HOLD vs. ELDN 44.3/100 HOLD) and 0.86β · 48% Vol risk profile, whereas ELDN leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: MIRM trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 62.7); meanwhile ELDN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MIRM vs ELDN
MIRM NASDAQ Head-to-Head Winner
Mirum Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$96.13
+0.65% 1D
Market Cap $6.2B
TTM Revenue $671M
Forward P/E N/M
Beta / 30D Vol 0.86β · 48% Vol
Unified Composite Score
51.1 / 100 HOLD
Tech 43.0 Fund 56.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 63
RSI-14: 62.7 · SMA20: $91.01 · SMA50: $88.19
ELDN NASDAQ
Eledon Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$1.78
-6.32% 1D
Market Cap $160.5M
TTM Revenue N/A
Forward P/E 5.4x
Beta / 30D Vol 1.78β · 116% Vol
Unified Composite Score
44.3 / 100 HOLD
Tech 33.0 Fund 55.0 Flow 64.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.2%), weak momentum, RSI 33
RSI-14: 32.8 · SMA20: $2.43 · SMA50: $2.47

6-Pillar Scorecard Institutional Category Breakdown (MIRM 2 – 3 ELDN)

Columns: Metric · MIRM · ELDN
1. Valuation Multiples ELDN
Forward P/E N/M 5.4x
Trailing P/E N/M 5.4x
PEG Ratio N/M N/M
EV / Revenue 10.0x N/M
2. Growth & Scale MIRM
Revenue Growth (YoY) +39.6% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $671M N/A
Market Cap $6.2B $160.5M
3. Profitability & Quality ELDN
Gross Margin 81.7% N/A
Operating Margin -21.6% 0.0%
Net Profit Margin -134.8% 0.0%
Return on Equity (ROE) -760.0% -105.7%
4. Balance Sheet & Cash Flow ELDN
Cash Generation (TTM) -$309M -$78M
Cash Flow Margin -46.0% N/A
Net Cash / Leverage $500M Net Debt $6.5M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MIRM
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 109.3% (15th %ile) 113.7% (28th %ile)
Put/Call OI Skew N/A 0.02x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MIRM (5) vs ELDN (5)
Institutional Metric MIRM ELDN Criterion Row Edge
Market Capitalization
Scale
$6.2B $160.5M Larger Scale MIRM
Trailing P/E Ratio
Valuation
N/M 5.4x Lower Multiple ELDN
Forward P/E Ratio
Valuation
N/M 5.4x Lower Multiple ELDN
Revenue Growth (YoY)
Growth
+39.6% +0.0% Higher Growth MIRM
Operating Margin (TTM)
Profitability
-21.6% 0.0% Higher Margin ELDN
Net Profit Margin
Profitability
-134.8% 0.0% Higher Margin ELDN
Return on Equity (ROE)
Capital Efficiency
-760.0% -105.7% Higher ROE ELDN
52-Week Range Position
Momentum
49% ($63–$130) 14% ($1–$4) Stronger Trend MIRM
Beta / 30D Volatility
Risk Regime
0.86β · 48% Vol 1.78β · 116% Vol Lower Realized Risk MIRM
Unified Institutional Score
Composite Signal
51.1 / 100 (HOLD) 44.3 / 100 (HOLD) Higher Composite MIRM
Trailing 12M Revenue (USD)
Operating Scale
$671M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
81.7% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 10.0x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$309M ($500M Net Debt) -$78M ($6.5M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MIRM +38.29 pp
MIRM: +15.68% · ELDN: -22.61%
3M Horizon MIRM +47.19 pp
MIRM: -0.61% · ELDN: -47.8%
6M Horizon MIRM +51.72 pp
MIRM: -2.52% · ELDN: -54.24%
1Y Horizon MIRM +21.64 pp
MIRM: +36.48% · ELDN: +14.84%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MIRM vs ELDN. Trailing 12-month operating profitability (MIRM -21.6% vs ELDN 0.0%) and valuation multiples (MIRM N/M vs ELDN 5.4x Forward P/E) are benchmarked directly in Pillar 4 below.

MIRM ADR TTM Benchmark FX-Normalized USD
TTM Revenue$671M
Gross Margin81.7%
Op. Margin-21.6%
ROE / Fwd P/E-760.0% · N/M
ELDN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-105.7% · 5.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MIRM CONSOLIDATION
96d in phase · OBV NEUTRAL
Current IV 109.3%
IV Percentile 15th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MIRM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ELDN BREAKDOWN
150d in phase · OBV DISTRIBUTION
Current IV 113.7%
IV Percentile 28th %ile
Put/Call OI Skew 0.02x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact ELDN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $91.58 · IV 50.6%

MIRM Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($9,158)

Compare $9,158 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 50.6% ATM IV.

5-DAY BULLISH SWING Liq B

Dec 18 $90 / $105 Bull Call Spread

Buy 1x $90C · Sell 1x $105C · 32d

Net Entry $640 Debit
T+5d @ +5% Move +$158 (+25%)
Max Risk / Buffer $640 Capped
5d Edge & Liquidity 0.6x R:R · Liq B
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq C

Dec 18 $85P / $95-$105C Seagull

Sell 1x $85P · Buy 1x $95/$105C · 32d

Net Entry $45 Credit
T+5d @ +5% Move +$262 (+18.8% RoM)
Max Risk / Buffer -7.2% Put Cushion ($1,394 Mgn)
5d Edge & Liquidity 0.9x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MIRM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $6.2B market capitalization and -21.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ELDN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $160.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MIRM vs ELDN Key Questions & Quantitative Answers

As of Nov 20, 2026, Mirum Pharmaceuticals, Inc. (MIRM) captures the overall head-to-head institutional edge over Eledon Pharmaceuticals, Inc. (ELDN) on higher Unified Composite conviction (51.1/100 HOLD vs. 44.3/100 HOLD) after splitting the core matrix 5–5 (led by Growth & Scale, Options & Positioning), while ELDN wins 3–2 across the 6-pillar growth and valuation breakdown. MIRM trades at $96.13 (N/M Forward P/E, -21.6% operating margin) versus ELDN at $1.78 (5.4x Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: MIRM earns the overall head-to-head edge with a stronger Unified Composite Score (51.1/100 HOLD vs. ELDN 44.3/100 HOLD) and 0.86β · 48% Vol risk profile, whereas ELDN leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MIRM trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 62.7); meanwhile ELDN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MIRM leads the Growth & Scale pillar: MIRM posts +39.6% YoY revenue growth and +0.0% YoY earnings growth on $671M TTM revenue (81.7% gross margin, -21.6% operating margin), compared with ELDN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, MIRM generates $671M in USD-normalized revenue versus N/A for ELDN. In operating R&D and SG&A reinvestment, MIRM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ELDN.

ELDN screens cheaper on headline valuation multiples. MIRM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 10.0x EV/Revenue (-46.0% FCF margin), whereas ELDN trades at 5.4x Forward P/E, 5.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MIRM (-760.0% ROE) versus ELDN (-105.7% ROE) capital efficiency.

In options market volatility and institutional positioning, MIRM carries 109.3% implied volatility (15th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.86β · 48% Vol realized risk). By comparison, ELDN carries 113.7% implied volatility (28th %ile, Balanced (25th–60th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.78β · 116% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.